The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Treatment of latent tuberculosis infection in HIV infected persons
Open accessAbstract
BACKGROUND: Individuals with human immunodeficiency virus (HIV) infection are at an increased risk of developing active tuberculosis (TB). It is known that treatment of latent TB infection (LTBI), also referred to as TB preventive therapy or chemoprophylaxis, helps to prevent progression to active disease in HIV negative populations. However, the extent and magnitude of protection (if any) associated with preventive therapy in those infected with HIV should be quantified. This present study is an update of the original review. OBJECTIVES: To determine the effectiveness of TB preventive therapy in reducing the risk of active tuberculosis and death in HIV-infected persons. SEARCH STRATEGY: This review was updated using the Cochrane Controlled Trials Register (CCTR), MEDLINE, EMBASE, AIDSLINE, AIDSTRIALS, AIDSearch, NLM Gateway and AIDSDRUGS (publication date from 01 July 2002 to 04 April 2008). We also scanned reference lists of articles and contacted authors and other researchers in the field in an attempt to identify additional studies that may be eligible for inclusion in this review. SELECTION CRITERIA: We included randomized controlled trials in which HIV positive individuals were randomly allocated to TB preventive therapy or placebo, or to alternative TB preventive therapy regimens. Participants could be tuberculin skin test positive or negative, but without active tuberculosis. DATA COLLECTION AND ANALYSIS: Three reviewers independently applied the study selection criteria, assessed study quality and extracted data. Effects were assessed using relative risk for dichotomous data and mean differences for continuous data. MAIN RESULTS: 12 trials were included with a total of 8578 randomized participants. TB preventive therapy (any anti-TB drug) versus placebo was associated with a lower incidence of active TB (RR 0.68, 95% CI 0.54 to 0.85). This benefit was more pronounced in individuals with a positive tuberculin skin test (RR 0.38, 95% CI 0.25 to 0.57) than in those who had a negative test (RR 0.89, 95% CI 0.64 to 1.24). Efficacy was similar for all regimens (regardless of drug type, frequency or duration of treatment). However, compared to INH monotherapy, short-course multi-drug regimens were much more likely to require discontinuation of treatment due to adverse effects. Although there was reduction in mortality with INH monotherapy versus placebo among individuals with a positive tuberculin skin test (RR 0.74, 95% CI 0.55 to 1.00) and with INH plus rifampicin versus placebo regardless of tuberculin skin test status (RR 0.69, 95% CI 0.50 to 0.95), overall, there was no evidence that TB preventive therapy versus placebo reduced all-cause mortality (RR 0.94, 95% CI 0.85 to 1.05). AUTHORS' CONCLUSIONS: Treatment of latent tuberculosis infection reduces the risk of active TB in HIV positive individuals especially in those with a positive tuberculin skin test. The choice of regimen will depend on factors such as availability, cost, adverse effects, adherence and drug resistance. Future studies should assess these aspects. In addition, trials evaluating the long-term effects of anti-tuberculosis chemoprophylaxis, the optimal duration of TB preventive therapy, the influence of level of immunocompromise on effectiveness and combination of anti-tuberculosis chemoprophylaxis with antiretroviral therapy are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Global Burden of Tuberculosis: Estimated Incidence, Prevalence, and Mortality by Country
Dye, C., Scheele, S., >Dolin, P., Pathania, V., Raviglione, M. C., & for the WHO Global Surveillance and Monitoring Project (1999) · JAMA · doi:10.1001/jama.282.7.677 · Cited by 2,947
Surveillance for waterborne-disease outbreaks--United States, 1993-1994.
Kramer, M. H., Herwaldt, B. L., Craun, G. F., Calderon, R. L., & Juranek, D. D. (1996) · PubMed · Cited by 2,152
Selwyn, P. A., Hartel, D., Lewis, V. A., Schoenbaum, E. E., Vermund, S. H., Klein, R. S., Walker, A. T., & Friedland, G. H. (1989) · New England Journal of Medicine · doi:10.1056/nejm198903023200901 · Cited by 1,574
Badri, M., Wilson, D., & Wood, R. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08904-3 · Cited by 556
Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection
Pape, J. W., Jean, S. S., Ho, J. L., Hafner, A., & Johnson, W. D. (1993) · The Lancet · doi:10.1016/0140-6736(93)91817-6 · Cited by 441
Diagnostic Standards and Classification of Tuberculosis
(1990) · American Review of Respiratory Disease · doi:10.1164/ajrccm/142.3.725 · Cited by 401
Whalen, C. C., Johnson, J. L., Okwera, A., Hom, D. L., Huebner, R., Mugyenyi, P., Mugerwa, R. D., Ellner, J. J., Nsubuga, P., Vjecha, M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709183371201 · Cited by 396
Lawn, S. D., Badri, M., & Wood, R. (2005) · AIDS · doi:10.1097/01.aids.0000194808.20035.c1 · Cited by 352
Halsey, N. A., Coberly, J. S., Desormeaux, J., Losikoff, P., Atkinson, J., Moulton, L. H., Contave, M., Johnson, M., Davis, H., Geiter, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(97)06532-x · Cited by 270
Isoniazid Preventive Therapy and Risk for Resistant Tuberculosis
Balcells, M. E., Thomas, S. L., Godfrey-Faussett, P., & Grant, A. D. (2006) · Emerging Infectious Diseases · doi:10.3201/eid1205.050681 · Cited by 238
Antiretroviral Drugs for Tuberculosis Control in the Era of HIV/AIDS
Williams, B. G., & Dye, C. (2003) · Science · doi:10.1126/science.1086845 · Cited by 235
Twice weekly tuberculosis preventive therapy in HIV infection in Zambia
Mwinga, A., Hosp, M., Godfrey-Faussett, P., Quigley, M., Mwaba, P., Mugala, B. N., Nyirenda, O., Luo, N., Pobee, J., Elliott, A. M., et al. (1998) · AIDS · doi:10.1097/00002030-199818000-00014 · Cited by 211
The Antiretroviral Therapy Cohort Collaboration (2005) · Clinical Infectious Diseases · doi:10.1086/498315 · Cited by 203
Gordin, F. M., Matts, J. P., Miller, C., Brown, L. S., Hafner, R., John, S. L., Klein, M., Vaughn, A., Besch, C. L., Perez, G., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707313370505 · Cited by 166
Fitzgerald, D. W., Desvarieux, M., Sévère, P., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02870-1 · Cited by 153
Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults
Hawken, M. P., Meme, H., Elliott, L. C., et al. (1997) · AIDS · doi:10.1097/00002030-199707000-00006 · Cited by 141
Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults
QUIGLEY, M. A., Mwinga, A., Kitchen, M., Lisse, I. M., Fuchs, D., Porter, J. D. H., & Godfrey‐Faussett, P. (2001) · AIDS · doi:10.1097/00002030-200101260-00011 · Cited by 131
Wilkinson, D., Squire, S. B., & Garner, P. (1998) · BMJ · doi:10.1136/bmj.317.7159.625 · Cited by 130
Grant, A. D., Charalambous, S., Fielding, K., Day, J. H., Corbett, E. L., Chaisson, R. E., Cock, K. M. D., Hayes, R., & Churchyard, G. (2005) · JAMA · doi:10.1001/jama.293.22.2719 · Cited by 126
Lessons Learned from Use of Highly Active Antiretroviral Therapy in Africa
Akileswaran, C. P., Lurie, M. N., Flanigan, T., & Mayer, K. H. (2005) · Clinical Infectious Diseases · doi:10.1086/431482 · Cited by 110
Tuberculosis Preventive Therapy in the Era of HIV Infection: Overview and Research Priorities
Churchyard, G., Scano, F., Grant, A. D., & Chaisson, R. E. (2007) · The Journal of Infectious Diseases · doi:10.1086/518662 · Cited by 83
Cochrane, G. M. (1995) · Journal of Hospital Infection · doi:10.1016/0195-6701(95)90298-8 · Cited by 73
Tuberculosis—Back to the future
Eisenach, K. D. (1995) · Human Pathology · doi:10.1016/0046-8177(95)90024-1 · Cited by 14
Cited by
Latent Mycobacterium tuberculosis Infection
Getahun, H., Matteelli, A., Chaisson, R. E., & Raviglione, M. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1405427 · Cited by 775
The Population Dynamics and Control of Tuberculosis
Dye, C., & Williams, B. G. (2010) · Science · doi:10.1126/science.1185449 · Cited by 604
Dheda, K., Barry, C. E., & Maartens, G. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00151-8 · Cited by 599
Montaner, J. S., Hogg, R., Wood, E., Kerr, T., Tyndall, M., Levy, A. R., & Harrigan, P. R. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69162-9 · Cited by 555
Karim, S. S. A., Churchyard, G. J., Karim, Q. A., & Lawn, S. D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60916-8 · Cited by 545
Metadata
- Authors
- Akolo, C., Adetifa, I., Shepperd, S., & Volmink, J.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2010-01-20
- Issue
- 1
- Pages
- CD000171-CD000171
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1920771564
- Cited by
- 713
- References
- 26
- FWCI
- 41.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.